Brief: LegoChem Biosciences, Takeda Enter into Multi-Target Research Collaboration and License Agreement

LigaChem Biosciences

22/03/2019 05:52

March 22 (Reuters) - LegoChem Biosciences Inc  141080.KQ :
    * LEGOCHEM BIOSCIENCES, TAKEDA ENTER INTO MULTI-TARGET
RESEARCH
AND LICENSE AGREEMENT FOR DEVELOPMENT OF ANTIBODY-DRUG
CONJUGATES IN IMMUNO-ONCOLOGY
    * TAKEDA OBTAINS RIGHTS TO LCB'S ADC PLATFORM FOR MULTIPLE
TARGETS
    * LCB WILL RECEIVE $7.25 MILLION IN UPFRONT AND NEAR-TERM
MILESTONE PAYMENTS.
    * LCB ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY,
COMMERCIAL
MILESTONE PAYMENTS OF UP TO $404 MILLION
    * LCB ELIGIBLE TO RECEIVE ROYALTIES ON SALES OF ANY
RESULTING ADC
PRODUCTS

Source text for Eikon:  ID:nBw6RwdWJa 
Further company coverage:  141080.KQ   4502.T 

 ((Reuters.Briefs@thomsonreuters.com;))